$3.18-0.12 (-3.64%)
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
Nuwellis, Inc. in the Healthcare sector is trading at $3.18 with a market capitalization of $1M. The stock is currently near its 52-week low of $2.80, remaining 95.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 6 is oversold, raising the odds of a near-term bounce. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.40Mβ | $2.42Mβ | $2.22Mβ | $1.73Mβ | $1.90M |
| Gross Profit | $1.68Mβ | $1.65Mβ | $1.45Mβ | $958,000β | $1.07M |
| Operating Income | -$4.57Mβ | -$2.44Mβ | -$2.70Mβ | -$2.91Mβ | -$3.06M |
| Net Income | -$4.54Mβ | -$2.42Mβ | $468,000β | -$12.55Mβ | -$3.01M |
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from...
Nuwellis Inc. (NASDAQ:NUWE) shares plunged 65.
Nuwellis Inc (NUWE) reports a 26% revenue increase and strategic acquisition, but faces liquidity constraints and rising operating expenses.
Moby summary of Nuwellis, Inc.'s Q1 2026 earnings call
Need a quote from a Motley Fool analyst? Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the first quarter ended 03/31/2026. In addition to myself, with us today are John L. Erb, Nuwellis' Chairman of the Board and our CFO, Carisa Schultz.
Moby summary of Nuwellis, Inc.'s Q4 2025 earnings call